CTOR

+ Watchlist + Portfolio

Citius Oncology, Inc.

Regulated industry Physical productsTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.98
52-Week Range: $0.49 – $2.25
Market Cap: $100.47M
P/E (TTM): —
EPS (TTM): -0.48
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 2.49
PEG Ratio: —
Return on Equity: -126.58%
Return on Assets: -29.12%
Gross Margin: 74.82%
Operating Margin: -595.55%
Profit Margin: 0.00%
Current Ratio: 0.73
Debt/Equity: 0.25
Total Debt: $10.21M
Free Cash Flow: $-31.17M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $94.12M

CTOR Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.43M	$4.24M	$4.93M	$6.42M
Selling, General & Admin	$1.43M	$7.88M	$15.65M	$17.10M
Operating Expenses	$4.86M	$12.12M	$20.57M	$23.52M
Operating Income	-$4.86M	-$12.12M	-$20.57M	-$23.52M
EBITDA	-$4.86M	-$12.12M	-$20.57M	-$23.49M
Pretax Income	-$4.86M	-$12.12M	-$20.57M	-$23.70M
Income Tax	$576.00K	$576.00K	$576.00K	$1.06M
Net Income	-$5.43M	-$12.70M	-$21.15M	-$24.76M
Diluted EPS	-0.08	-0.18	-0.31	-0.34
Diluted Shares	71.24M	71.24M	68.05M	73.27M

CTOR Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$0.00	$0.00	$112.00	$3.92M
Inventory	—	$0.00	$8.27M	$22.29M
Current Assets	$2.69M	$7.73M	$10.97M	$27.54M
Total Assets	$42.69M	$47.73M	$84.37M	$100.94M
Current Liabilities	$5.85M	$21.05M	$32.70M	$49.49M
Long-Term Debt	—	—	$3.80M	$3.80M
Total Debt	—	—	$3.80M	$3.80M
Total Liabilities	$6.42M	$22.20M	$38.23M	$56.08M
Retained Earnings	-$5.43M	-$18.13M	-$39.28M	-$64.04M
Shareholders' Equity	$36.27M	$25.54M	$46.14M	$44.87M
Working Capital	-$3.16M	-$13.31M	-$21.73M	-$21.95M
Net Debt	—	—	$3.80M	—

CTOR Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$0.00	$0.00	$126.35K	-$5.49M
Capital Expenditure	—	—	-$5.00M	-$5.75M
Free Cash Flow	$0.00	$0.00	-$4.87M	-$11.24M
Stock-Based Compensation	$0.00	$1.97M	$7.50M	$8.32M
Investing Cash Flow	—	$0.00	-$5.00M	-$5.75M
Financing Cash Flow	—	$0.00	$4.87M	$15.17M
Net Change in Cash	—	—	$112.00	$3.92M

CTOR Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$3.94M	$1.67M	$1.49M
Cost of Revenue	$0.00	$0.00	—	$789.21K	$328.88K	$491.84K
Gross Profit	$0.00	$0.00	—	$3.15M	$1.34M	$1.00M
Research & Development	$3.14M	$938.28K	$1.08M	$1.02M	$1.08M	$218.50K
Selling, General & Admin	$4.33M	$4.01M	$3.64M	$6.82M	$27.15M	$7.78M
Operating Expenses	$7.47M	$4.94M	$4.71M	$8.41M	$29.95M	$9.72M
Operating Income	-$7.47M	-$4.94M	-$4.71M	-$5.25M	-$28.61M	-$8.72M
EBITDA	-$7.47M	-$4.94M	-$4.68M	-$4.65M	-$25.09M	-$6.72M
Pretax Income	-$7.47M	-$5.11M	-$4.73M	-$5.27M	-$26.84M	-$9.03M
Income Tax	$264.24K	$264.24K	$264.24K	$264.24K	-$231.21K	-$107.35K
Net Income	-$7.74M	-$5.37M	-$5.00M	-$5.53M	-$26.61M	-$8.92M
Diluted EPS	-0.11	-0.08	—	-0.06	-0.27	-0.08
Diluted Shares	71.55M	71.55M	—	87.46M	100.03M	107.89M

CTOR Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$112.00	$112.00	$3.92M	$7.30M	$2.63M	$16.56M
Receivables	—	—	—	$4.05M	$1.08M	$686.24K
Inventory	$15.34M	$17.21M	$22.29M	$22.64M	$22.66M	$22.63M
Current Assets	$18.04M	$18.31M	$27.54M	$37.15M	$29.42M	$42.71M
Total Assets	$91.44M	$91.71M	$100.94M	$109.97M	$100.70M	$112.09M
Current Liabilities	$49.74M	$52.99M	$49.49M	$44.71M	$58.81M	$58.79M
Long-Term Debt	$3.80M	$3.80M	$3.80M	$3.80M	$3.80M	$10.21M
Total Debt	$3.80M	$3.80M	$3.80M	$3.80M	$3.80M	$10.21M
Total Liabilities	$55.80M	$59.31M	$56.08M	$51.56M	$65.43M	$71.71M
Retained Earnings	-$53.67M	-$59.04M	-$64.04M	-$69.57M	-$96.18M	-$105.11M
Shareholders' Equity	$35.64M	$32.40M	$44.87M	$58.41M	$35.27M	$40.38M
Working Capital	-$31.70M	-$34.68M	-$21.95M	-$7.56M	-$29.39M	-$16.08M
Net Debt	$3.80M	$3.80M	—	—	$1.17M	—

CTOR Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$0.00	$0.00	-$5.49M	-$7.35M	-$3.83M	-$2.71M
Capital Expenditure	—	—	—	-$4.40M	-$600.00K	-$2.00M
Free Cash Flow	$0.00	$0.00	-$11.24M	-$11.75M	-$4.43M	-$4.71M
Depreciation & Amortisation	$0.00	$0.00	—	$573.44K	$1.72M	$1.90M
Stock-Based Compensation	$2.09M	$2.13M	$2.30M	$3.96M	$3.53M	$3.56M
Investing Cash Flow	$0.00	$0.00	—	-$4.40M	-$600.00K	-$2.00M
Financing Cash Flow	$0.00	$0.00	—	$15.13M	-$231.20K	$18.64M
Net Change in Cash	—	—	—	$3.37M	-$4.66M	$13.93M

Market Snapshot

About

Citius Oncology, Inc. is a biopharmaceutical company focused on developing and commercializing anti-cancer therapies. The company is headquartered in Cranford, New Jersey. Citius Oncology's pipeline includes novel treatments targeting solid tumors and hematological malignancies. The company emphasizes innovative drug formulations and combination therapies designed to improve patient outcomes in oncology.